Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PZ-2645
- Development stage
- Preclinical
- Lead developer
- Helmholtz Centre for Infection Research
- Modality
- Small Molecules
01
Overview
PZ-2645 is a novel, enantiomerically pure arylurea derivative of aryloxy(1-phenylpropyl) alicyclic diamine, representing the S-enantiomer of the racemic mixture PZ-1985. Developed by researchers at the Jagiellonian University Medical College in collaboration with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), PZ-2645 is being investigated as a preclinical candidate for the treatment of resistant *Staphylococcus aureus* infections, including methicillin-resistant *Staphylococcus aureus* (MRSA). The compound exhibits potent antibacterial activity, improved metabolic stability, and low cytotoxicity against mammalian cells. Its mechanism of action involves bacterial membrane depolarization, leading to rapid bactericidal effects.
- Other names
- (S)-PZ-1985S-PZ-1985S-PZ1985S-PZ 1985
Beyond the preview
Go deeper on PZ-2645.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PZ-2645.